Your browser doesn't support javascript.
loading
Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK-3ß/TTBK1 pathway and decreasing Tau hyperphosphorylation in high-fat diet- streptozocin rat model.
Moghazy, Hoda M; Abdelhaliem, Nesreen G; Mohammed, Sherine Ahmed; Hassan, Asmaa; Abdelrahman, Amany.
Afiliação
  • Moghazy HM; Department of Physiology, Faculty of Medicine, Sohag University, Sohag, 82524, Egypt.
  • Abdelhaliem NG; Department of Histology, Faculty of Medicine, Sohag University, Sohag, Egypt.
  • Mohammed SA; Department of Histology, Faculty of Medicine, Sohag University, Sohag, Egypt.
  • Hassan A; Department of Physiology, Faculty of Medicine, Sohag University, Sohag, 82524, Egypt.
  • Abdelrahman A; Department of Physiology, Faculty of Medicine, Sohag University, Sohag, 82524, Egypt. amany_abdelhameed@med.sohag.edu.eg.
Pflugers Arch ; 476(5): 779-795, 2024 May.
Article em En | MEDLINE | ID: mdl-38536493
ABSTRACT
The American Diabetes Association guidelines (2021) confirmed the importance of raising public awareness of diabetes-induced cognitive impairment, highlighting the links between poor glycemic control and cognitive impairment. The characteristic brain lesions of cognitive dysfunction are neurofibrillary tangles (NFT) and senile plaques formed of amyloid-ß deposition, glycogen synthase kinase 3 beta (GSK3ß), and highly homologous kinase tau tubulin kinase 1 (TTBK1) can phosphorylate Tau proteins at different sites, overexpression of these enzymes produces extensive phosphorylation of Tau proteins making them insoluble and enhance NFT formation, which impairs cognitive functions. The current study aimed to investigate the potential contribution of liraglutide and pramlintide in the prevention of diabetes-induced cognitive dysfunction and their effect on the PI3K/AKT/GSK-3ß/TTBK1 pathway in type 2 diabetic (T2D) rat model. T2D was induced by administration of a high-fat diet for 10 weeks, then injection of a single dose of streptozotocin (STZ); treatment was started with either pramlintide (200 µg/kg/day sc) or liraglutide (0.6 mg/kg/day sc) for 6 weeks in addition to the HFD. At the end of the study, cognitive functions were assessed by novel object recognition and T-maze tests. Then, rats were sacrificed for biochemical and histological assessment of the hippocampal tissue. Both pramlintide and liraglutide treatment revealed equally adequate control of diabetes, prevented the decline in memory function, and increased PI3K/AKT expression while decreasing GSK-3ß/TTBK1 expression; however, liraglutide significantly decreased the number of Tau positive cells better than pramlintide did. This study confirmed that pramlintide and liraglutide are promising antidiabetic medications that could prevent associated cognitive disorders in different mechanisms.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas tau / Fosfatidilinositol 3-Quinases / Proteínas Proto-Oncogênicas c-akt / Disfunção Cognitiva / Dieta Hiperlipídica / Liraglutida / Glicogênio Sintase Quinase 3 beta Limite: Animals Idioma: En Revista: Pflugers Arch Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Egito País de publicação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas tau / Fosfatidilinositol 3-Quinases / Proteínas Proto-Oncogênicas c-akt / Disfunção Cognitiva / Dieta Hiperlipídica / Liraglutida / Glicogênio Sintase Quinase 3 beta Limite: Animals Idioma: En Revista: Pflugers Arch Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Egito País de publicação: Alemanha